Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Rhea-AI Summary

Novavax (NASDAQ: NVAX) has scheduled its first quarter 2025 financial results and operational highlights conference call for May 8, 2025, at 8:30 a.m. Eastern Time. Participants can join through phone registration or direct dial-in, with connection recommended 10 minutes before the start time.

A replay of the conference call will be available from 11:30 a.m. ET on May 8 until 11:59 p.m. ET on May 15, 2025. The webcast replay will remain accessible through June 7, 2025, on the company's investor relations website.

GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows:

Conference call details:
Date:	May 8, 2025
Time:	8:30 a.m. U.S. ET
URL to register phone:	https://emportal.ink/43UHjFq
Dial-in number:	(800) 836-8184 (Domestic) or
	(+1) (646) 357-8785 (International)
Webcast:	ir.novavax.com/events

• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

Replay details:
Date:	Available starting at 11:30 a.m. U.S. ET, May 8, 2025, until 11:59 p.m. U.S. ET, May 15, 2025
Dial-in number:	(888) 660-6345 (Domestic) or
	(+1) (646) 517-4150 (International)
Passcode:	88407#
Webcast:	ir.novavax.com/events, until June 7, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, which includes protein-based nanoparticles and its Matrix-M^® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors 
Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-report-first-quarter-2025-financial-results-on-may-8-2025-302443439.html

SOURCE Novavax, Inc.

FAQ

When will Novavax (NVAX) report Q1 2025 earnings?

Novavax will report its Q1 2025 earnings on Thursday, May 8, 2025, at 8:30 a.m. Eastern Time.

How can I access Novavax's Q1 2025 earnings call?

You can access the call by registering at https://emportal.ink/43UHjFq, or by dialing (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International). A webcast is also available at ir.novavax.com/events.

How long will Novavax's Q1 2025 earnings call replay be available?

The phone replay will be available from May 8, 11:30 a.m. ET until May 15, 11:59 p.m. ET. The webcast replay will be accessible until June 7, 2025.

What is the replay dial-in number for Novavax's Q1 2025 earnings call?

The replay dial-in numbers are (888) 660-6345 (Domestic) or (+1) (646) 517-4150 (International), with passcode 88407#.